Myofilament dysfunction contributes to impaired myocardial contraction in the infarct border zone

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 307, Issue 8, 2014, Pages H1150-H1158

  Shimkunas, Rafael ^a,b   Makwana, Om ^a,b   Spaulding, Kimberly ^a,b   Bazargan, Mona ^a,b   Khazalpour, Michael ^a,b   Takaba, Kiyoaki ^a,b   Soleimani, Mehrdad ^a,b   Myagmar, Bat Erdene ^a,b   Lovett, David H ^a,b   Simpson, Paul C ^a,b   Ratcliffe, Mark B ^a,b   Baker, Anthony J ^a,b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Contraction; Essential light chain; Infarct; Matrix metalloproteinase; Myofilament

Indexed keywords

ADENOSINE TRIPHOSPHATE; DOXYCYCLINE; GELATINASE A; MATRIX METALLOPROTEINASE; MYOSIN; MYOSIN LIGHT CHAIN; MATRIX METALLOPROTEINASE INHIBITOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART CONTRACTION; HEART INFARCTION; HEART MUSCLE CONTRACTILE FORCE; IN VITRO STUDY; MALE; MUSCLE ISOMETRIC CONTRACTION; MUSCLE ISOTONIC CONTRACTION; MUSCLE RIGIDITY; MYOFILAMENT; NONHUMAN; PROTEIN PHOSPHORYLATION; SHEEP; ANIMAL; DRUG EFFECTS; METABOLISM; MUSCLE FIBRIL; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION;

ADENOSINE TRIPHOSPHATE; ANIMALS; DOXYCYCLINE; MALE; MATRIX METALLOPROTEINASE INHIBITORS; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOFIBRILS; MYOSIN LIGHT CHAINS; PHOSPHORYLATION; SHEEP;

EID: 84908102107     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00463.2014     Document Type: Article

References (27)

1. Baker AJ. Adrenergic signaling in heart failure: a balance of toxic and protective effects. Pflügers Arch 466: 1139-1150, 2014.
2. Belin RJ, Sumandea MP, Kobayashi T, Walker LA, Rundell VL, Urboniene D, Yuzhakova M, Ruch SH, Geenen DL, Solaro RJ, de Tombe PP. Left ventricular myofilament dysfunction in rat experimental hypertrophy and congestive heart failure. Am J Physiol Heart Circ Physiol 291: H2344-H2353, 2006.
3. Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A, Dahi S, Karliner JS, Lovett DH. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 292: H1847-H1860, 2007.
4. 2+ on cross-bridge turnover kinetics in skinned single rabbit psoas fibers: implications for regulation of muscle contraction. Proc Natl Acad Sci USA 85: 3265-3269, 1988.
5. Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol 147: 325-338, 1995.
6. Gao WD, Dai T, Nyhan D. Increased cross-bridge cycling rate in stunned myocardium. Am J Physiol Heart Circ Physiol 290: H886-H893, 2006.
7. Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res 63: 102-107, 2011.
8. Guccione JM, Moonly SM, Moustakidis P, Costa KD, Moulton MJ, Ratcliffe MB, Pasque MK. Mechanism underlying mechanical dysfunction in the border zone of left ventricular aneurysm: a finite element model study. Ann Thorac Surg 71: 654-662, 2001.
9. Hamdani N, de Waard M, Messer AE, Boontje NM, Kooij V, van Dijk S, Versteilen A, Lamberts R, Merkus D, Dos Remedios C, Duncker DJ, Borbely A, Papp Z, Paulus W, Stienen GJ, Marston SB, van der Velden J. Myofilament dysfunction in cardiac disease from mice to men. J Muscle Res Cell Motil 29: 189-201, 2008.
10. Hayashidani S, Tsutsui H, Shiomi T, Ikeuchi M, Matsusaka H, Suematsu N, Wen J, Egashira K, Takeshita A. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 108: 2134-2140, 2003.
11. Hu Q, Wang X, Lee J, Mansoor A, Liu J, Zeng L, Swingen C, Zhang G, Feygin J, Ochiai K, Bransford TL, From AH, Bache RJ, Zhang J. Profound bioenergetic abnormalities in peri-infarct myocardial regions. Am J Physiol Heart Circ Physiol 291: H648-H657, 2006.
12. Huxley AF. Muscle structure and theories of contraction. Prog Biophys Biophys Chem 7: 255-318, 1957.
13. Jackson BM, Gorman JH, 3rd Salgo IS, Moainie SL, Plappert T, St John-Sutton M, Edmunds LH Jr, Gorman RC. Border zone geometry increases wall stress after myocardial infarction: contrast echocardiographic assessment. Am J Physiol Heart Circ Physiol 284: H475-H479, 2003.
14. Jackson BM, Gorman JH, Moainie SL, Guy TS, Narula N, Narula J, John-Sutton MG, Edmunds LH Jr, Gorman RC. Extension of borderzone myocardium in postinfarction dilated cardiomyopathy. J Am Coll Cardiol 40: 1160-1171, 2002.
15. Kazmierczak K, Muthu P, Huang W, Jones M, Wang Y, Szczesna-Cordary D. Myosin regulatory light chain mutation found in hypertrophic cardiomyopathy patients increases isometric force production in transgenic mice. Biochem J 442: 95-103, 2012.
16. Kazmierczak K, Xu Y, Jones M, Guzman G, Hernandez OM, Kerrick WG, Szczesna-Cordary D. The role of the N-terminus of the myosin essential light chain in cardiac muscle contraction. J Mol Biol 387: 706-725, 2009.
17. Kim YK, Kim SJ, Kramer CM, Yatani A, Takagi G, Mankad S, Szigeti GP, Singh D, Bishop SP, Shannon RP, Vatner DE, Vatner SF. Altered excitation-contraction coupling in myocytes from remodeled myocardium after chronic myocardial infarction. J Mol Cell Cardiol 34: 63-73, 2002.
18. Lee LC, Wenk JF, Klepach D, Zhang Z, Saloner D, Wallace AW, Ge L, Ratcliffe MB, Guccione JM. A novel method for quantifying in-vivo regional left ventricular myocardial contractility in the border zone of a myocardial infarction. J Biomech Eng 133: 094506, 2011.
19. Lopez JE, Myagmar BE, Swigart PM, Montgomery MD, Haynam S, Bigos M, Rodrigo MC, Simpson PC. β-Myosin heavy chain is induced by pressure overload in a minor subpopulation of smaller mouse cardiac myocytes. Circ Res 109: 629-638, 2011.
20. Markovitz LJ, Savage EB, Ratcliffe MB, Bavaria JE, Kreiner G, Iozzo RV, Hargrove WC 3rd, Bogen DK, Edmunds LH, Jr. Large animal model of left ventricular aneurysm. Ann Thorac Surg 48: 838-845, 1989.
21. Meder B, Laufer C, Hassel D, Just S, Marquart S, Vogel B, Hess A, Fishman MC, Katus HA, Rottbauer W. A single serine in the carboxyl terminus of cardiac essential myosin light chain-1 controls cardiomyocyte contractility in vivo. Circ Res 104: 650-659, 2009.
22. Muthu P, Wang L, Yuan CC, Kazmierczak K, Huang W, Hernandez OM, Kawai M, Irving TC, Szczesna-Cordary D. Structural and functional aspects of the myosin essential light chain in cardiac muscle contraction. FASEB J 25: 4394-4405, 2011.
23. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, Szczesna-Cordary D, Schulz R. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 112: 544-552, 2005.
24. Sun K, Zhang Z, Suzuki T, Wenk JF, Stander N, Einstein DR, Saloner DA, Wallace AW, Guccione JM, Ratcliffe MB. Dor procedure for dyskinetic anteroapical myocardial infarction fails to improve contractility in the border zone. J Thorac Cardiovasc Surg 140: 233-239, 239 e231-234, 2010.
25. Walker LA, Medway AM, Walker JS, Cleveland JC Jr, Buttrick PM. Tissue procurement strategies affect the protein biochemistry of human heart samples. J Muscle Res Cell Motil 31: 309-314, 2011.
26. Wang GY, Bergman MR, Nguyen AP, Turcato S, Swigart PM, Rodrigo MC, Simpson PC, Karliner JS, Lovett DH, Baker AJ. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res 69: 688-696, 2006.
27. Zhang Z, Sun K, Saloner DA, Wallace AW, Ge L, Baker AJ, Guccione JM, Ratcliffe MB. The benefit of enhanced contractility in the infarct borderzone: a virtual experiment. Front Physiol 3: 86, 2012.